{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:34Z","timestamp":1792173514582,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most pathogens mutate and evolve over time to escape immune and drug pressure. To achieve this, they alter specific hotspot residues in their intracellular proteins to render the targeted drug(s) ineffective and develop resistance. Such hotspot residues may be located as a cluster or uniformly as a signature of adaptation in a protein. Identifying the hotspots and signatures is extremely important to comprehensively understand the disease pathogenesis and rapidly develop next-generation therapeutics. As experimental methods are time-consuming and often cumbersome, there is a need to develop efficient computational protocols and adequately utilize them. To address this issue, we present a unique computational protein design protocol that identifies hotspot residues, resistance mutations and signatures of adaptation in a pathogen\u2019s protein against a bound drug. Using the protocol, the binding affinity between the designed mutants and drug is computed quickly, which offers predictions for comparison with biophysical experiments. The applicability and accuracy of the protocol are shown using case studies of a few protein\u2013drug complexes. As a validation, resistance mutations in severe acute respiratory syndrome coronavirus 2 main protease (Mpro) against narlaprevir (an inhibitor of hepatitis C NS3\/4A serine protease) are identified. Notably, a detailed methodology and description of the working principles of the protocol are presented. In conclusion, our protocol will assist in providing a first-hand explanation of adaptation, hotspot-residue variations and surveillance of evolving resistance mutations in a pathogenic protein.<\/jats:p>","DOI":"10.1093\/bfgp\/elac020","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T01:58:40Z","timestamp":1658195920000},"page":"195-203","source":"Crossref","is-referenced-by-count":20,"title":["A comprehensive protein design protocol to identify resistance mutations and signatures of adaptation in pathogens"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-2547","authenticated-orcid":false,"given":"Aditya K","family":"Padhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5559-289X","authenticated-orcid":false,"given":"Timir","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"a018077","DOI":"10.1101\/cshperspect.a018077","article-title":"Mutation--the engine of evolution: studying mutation and its role in the evolution of bacteria","volume":"7","author":"Hershberg","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrg3734","article-title":"Natural selection and infectious disease in human populations","volume":"15","author":"Karlsson","year":"2014","journal-title":"Nat Rev Genet"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrg3564","article-title":"Genome dynamics during experimental evolution","volume":"14","author":"Barrick","year":"2013","journal-title":"Nat Rev Genet"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"aad3292","DOI":"10.1126\/science.aad3292","article-title":"Multidrug evolutionary strategies to reverse antibiotic resistance","volume":"351","author":"Baym","year":"2016","journal-title":"Science"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"64116","DOI":"10.7554\/eLife.64116","article-title":"Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens","volume":"10","author":"Igler","year":"2021","journal-title":"elife"},{"issue":"2022","key":"2023041318221273900_","first-page":"2025","article-title":"A computational method for predicting the most likely evolutionary trajectories in the stepwise accumulation of resistance mutations","volume":"2022","author":"Eccleston","year":"2001","journal-title":"bioRxiv"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.643849","article-title":"Application of computational methods in understanding mutations in Mycobacterium tuberculosis drug resistance","volume":"8","author":"Mugumbate","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1021\/jp102546s","article-title":"Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors","volume":"114","author":"Hao","year":"2010","journal-title":"J Phys Chem B"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s42003-019-0743-5","article-title":"A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein","volume":"3","author":"Liu","year":"2020","journal-title":"Commun Biol"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"13707","DOI":"10.1073\/pnas.1002162107","article-title":"Predicting resistance mutations using protein design algorithms","volume":"107","author":"Frey","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12859-021-04137-0","article-title":"Predicting rifampicin resistance mutations in bacterial RNA polymerase subunit beta based on majority consensus","volume":"22","author":"Ning","year":"2021","journal-title":"BMC Bioinformatics"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1021\/acsptsci.0c00113","article-title":"Can SARS-CoV-2 accumulate mutations in the S-protein to increase pathogenicity?","volume":"3","author":"Padhi","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV-2 vaccines and the growing threat of viral variants","volume":"325","author":"Moore","year":"2021","journal-title":"JAMA"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"101992","DOI":"10.1016\/j.isci.2020.101992","article-title":"High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance","volume":"24","author":"Padhi","year":"2021","journal-title":"iScience"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/1873-3468.14182","article-title":"Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination","volume":"595","author":"Padhi","year":"2021","journal-title":"FEBS Lett"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbrc.2021.03.118","article-title":"Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation","volume":"555","author":"Padhi","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"9141","DOI":"10.1039\/D2CP00171C","article-title":"High-throughput design of symmetrical dimeric SARS-CoV-2 main protease: structural and physical insights into hotspots for adaptation and therapeutics","volume":"24","author":"Padhi","year":"2022","journal-title":"Phys Chem Chem Phys"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021946118","article-title":"Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP","volume":"118","author":"Naydenova","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat Commun"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802608786786624","article-title":"Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery","volume":"8","author":"Vilar","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0006-3495(94)80923-3","article-title":"Efficient rotamer elimination applied to protein side-chains and related spin glasses","volume":"66","author":"Goldstein","year":"1994","journal-title":"Biophys J"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-2836(02)00442-4","article-title":"Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations","volume":"320","author":"Guerois","year":"2002","journal-title":"J Mol Biol"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/prot.22234","article-title":"Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures","volume":"75","author":"Labute","year":"2009","journal-title":"Proteins"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0959-440X(02)00344-5","article-title":"Rotamer libraries in the 21st century","volume":"12","author":"Dunbrack","year":"2002","journal-title":"Curr Opin Struct Biol"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1006\/jmbi.1993.1170","article-title":"Backbone-dependent rotamer library for proteins. Application to side-chain prediction","volume":"230","author":"Dunbrack","year":"1993","journal-title":"J Mol Biol"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2","article-title":"The penultimate rotamer library","volume":"40","author":"Lovell","year":"2000","journal-title":"Proteins"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/jcc.20933","article-title":"The generalized born\/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area","volume":"29","author":"Labute","year":"2008","journal-title":"J Comput Chem"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/gch2.1018","article-title":"Data, disease and diplomacy: GISAID\u2019s innovative contribution to global health","volume":"1","author":"Elbe","year":"2017","journal-title":"Global Chall"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"2023041318221273900_","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Briefings in Functional Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bfg\/article-pdf\/22\/2\/195\/49873557\/elac020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bfg\/article-pdf\/22\/2\/195\/49873557\/elac020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T13:46:41Z","timestamp":1700833601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bfg\/article\/22\/2\/195\/6645816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,18]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/bfgp\/elac020","relation":{},"ISSN":["2041-2649","2041-2657"],"issn-type":[{"value":"2041-2649","type":"print"},{"value":"2041-2657","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,7,18]]}}}